The Department of Veterans Affairs (VA) awarded an Indefinite Delivery Contract (IDC) worth up to $147,080 to Natera Inc. to provide next generation sequencing and peripheral blood circulating tumor DNA (ctDNA) testing services in support of a VA-funded research study. The contract has a single award, no set-aside, and a period of performance from March 2025 to March 2028.
The initial delivery order under this IDC is for $496,460 to fund research and development activities related to minimal residual disease testing through Fiscal Year 2024. A separate $2.8 million delivery order was also awarded to provide ctDNA testing services using Natera's Signatera assay, a highly sensitive and personalized ctDNA platform, to analyze patient blood samples from the RIVAL study. This study aims to evaluate whether ctDNA clearance can predict progression-free survival in veterans with locally advanced non-small cell lung cancer across seven VA medical centers. Natera was selected as the sole source provider due to its prior work analyzing baseline samples for the study under a separate National Precision Oncology Program contract, ensuring data consistency.
Generated 2/28/25, 9:53 AM